Translational research studies of erbB oncogenes: selection strategies for breast cancer treatment.
Specific gene families, e.g. encoding members of signal transduction pathways, show a gene dosage sensitivity. We report on the determination of the gene dosages of egfr and c-erbB-2 in relation to the intratumoral concentration of the tyrosine kinase receptor protein EGFR and p185c-erbB-2 and the clinical outcome of breast cancer patients in a retrospective study. Prognostic unfavorable subgroups were determined in a life-table analysis by (a) an average gene copy number of egfr of less than 0.4 and greater than 1.6 and an intratumoral EGFR concentration of more than 56 fmol/mg, (b) an intratumoral p185c-erbB-2 concentration above 26 HNU/mg and (c) a quotient of egfr and c-erbB-2 average gene copy numbers of less than 0.15 and greater than 4.35.
Brandt
B H
BH
Institut für Klinische Chemie und Laboratoriumsmedizin, Westf. Wilh.-Universität Münster, Germany. brandt@uni-muenster.de
Beckmann
A
A
Gebhardt
F
F
Rötger
A
A
Jackisch
C
C
Assmann
G
G
Zänker
K S
KS
D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D004261:DNA Replication; D004273:DNA, Neoplasm / Q000235:genetics; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000235:genetics*; D005784:Gene Amplification; D018628:Gene Dosage; D018815:Genes, erbB; D006801:Humans; D019656:Loss of Heterozygosity; D009362:Neoplasm Metastasis; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*
D004273:DNA, Neoplasm; D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases